Rosetta Genomics (NASDAQ:ROSG) today announced that the United
States Patent and Trademark Office has allowed claims in two patent
applications.
“Rosetta Genomics owns or has access to intellectual property related to
microRNAs that is among the broadest of any commercial entity, and these
two notices of allowance further solidify our position”
The first, covering human microRNA miR-21, was derived from the “Tuschl
III” patent series that is assigned to the Max Planck Society, Berlin,
Germany and is used in Rosetta’s miRview™ mets and miRview™ squamous
diagnostic assays. Rosetta holds a co-exclusive license to miR-21 in
diagnostic applications, and a non-exclusive license for the research
use field. The second patent application, covering Sanger viral
hcmv-miR-UL112 and its precursor, was shown to suppress the human (host)
immune system during viral infection. The allowed claims are directed to
the miR, its hairpin, its complement, a DNA encoding the same, a
sequence 80% identical to, a vector and a probe comprising the same.
“Rosetta Genomics owns or has access to intellectual property related to
microRNAs that is among the broadest of any commercial entity, and these
two notices of allowance further solidify our position,” said Kenneth A.
Berlin, president and chief executive officer. “Our patent applications
and issued patents cover approximately 51% of publicly registered
microRNAs, plus 168 non-public, newly discovered microRNAs. microRNAs
are at the forefront of an exciting revolution in personalized medicine
and we believe that Rosetta is leading the way in diagnostic uses as we
harness this knowledge to advance our deep pipeline of products.”
Rosetta Genomics has filed more than 20 patent applications worldwide to
protect each aspect of its commercial diagnostic products. Many of these
applications protect the specific microRNAs used in the company’s
products. In addition, the company is pursuing more than 50 patent
applications to protect methods of detecting microRNAs and methods of
diagnosing and treating diseases with microRNAs.
MIT team creates efficient technique for identifying causal gene relationships